Effect of aspirin treatment duration on clinical outcomes in acute coronary syndrome patients with early aspirin discontinuation and received P2Y12 inhibitor monotherapy

被引：0

作者：

Chen, P. -W. ^{[1
]}

Ho, M. -Y. ^{[2
]}

Feng, W. -H. ^{[3
]}

Su, C. -H. ^{[4
]}

Huang, S. -W. ^{[4
]}

Cheng, C. -W. ^{[5
]}

Yeh, H. -I. ^{[5
]}

Chen, C. -P. ^{[6
]}

Huang, W. -C. ^{[7
]}

Fang, C. -C. ^{[8
]}

Lin, H. -W. ^{[1
]}

Lin, S. -H. ^{[1
]}

Hsieh, I. -C. ^{[2
]}

Li, Y. -H. ^{[1
]}

机构：

[1] Natl Cheng Kung Univ Hosp, Tainan, Taiwan

[2] Chang Gung Univ, Chang Gung Mem Hosp, Coll Med, taoyuan, Taiwan

[3] Kaohsiung Med Univ Hosp, Kaohsiung, Taiwan

[4] Chung Shan Med Univ Hosp, Taichung, Taiwan

[5] Mackay Mem Hosp, Taipei, Taiwan

[6] Changhua Christian Hosp, Changhua, Taiwan

[7] Kaohsiung Vet Gen Hosp, Kaohsiung, Taiwan

[8] Tainan Municipal Hosp, Tainan, Taiwan

来源：

EUROPEAN HEART JOURNAL | 2021年 / 42卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1208 / 1208

页数：1

共 50 条

[1] Effect of aspirin treatment duration on clinical outcomes in acute coronary syndrome patients with early aspirin discontinuation and received P2Y12 inhibitor monotherapy
Ho, Ming-Yun
Chen, Po-Wei
Feng, Wen-Han
Su, Chun-Hung
Huang, Sheng-Wei
Cheng, Chung-Wei
Yeh, Hung-I
Chen, Ching-Pei
Huang, Wei-Chun
Fang, Ching-Chang
Lin, Hui-Wen
Lin, Sheng-Hsiang
Hsieh, I-Chang
Li, Yi-Heng
PLOS ONE, 2021, 16 (05):
[2] P2Y12 INHIBITOR MONOTHERAPY VERSUS CONVENTIONAL DUAL ANTIPLATELET THERAPY OR ASPIRIN MONOTHERAPY IN ACUTE CORONARY SYNDROME
Song, P. -S.
ATHEROSCLEROSIS, 2021, 331 : E266 - E266
[3] P2Y12 Inhibitor or Aspirin Monotherapy for Secondary Prevention of Coronary Events
Gragnano, Felice
Cao, Davide
Pirondini, Leah
Franzone, Anna
Kim, Hyo-Soo
von Scheidt, Moritz
Pettersen, Alf-Age R.
Zhao, Qiang
Woodward, Mark
Chiarito, Mauro
McFadden, Eugene P.
Park, Kyung Woo
Kastrati, Adnan
Seljeflot, Ingebjorg
Zhu, Yunpeng
Windecker, Stephan
Kang, Jeehoon
Schunkert, Heribert
Arnesen, Harald
Bhatt, Deepak L.
Steg, Philippe Gabriel
Calabro, Paolo
Pocock, Stuart
Mehran, Roxana
Valgimigli, Marco
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2023, 82 (02) : 89 - 105
[4] P2Y12 Inhibitor or Aspirin Monotherapy in Patients with Coronary Artery Disease: is it Time for a Paradigm Shift?
Gragnano, Felice
Capolongo, Antonio
Calabro, Paolo
CURRENT VASCULAR PHARMACOLOGY, 2024, 22 (01) : 1 - 4
[5] P2Y12 Inhibitor Monotherapy after Percutaneous Coronary Intervention: Is It Safe to Abandon Aspirin?
Feng, Wen-Han
Hsieh, I-Chang
Li, Yi-Heng
ACTA CARDIOLOGICA SINICA, 2021, 37 (01) : 1 - 8
[6] Aspirin versus P2Y12 inhibitor-based monotherapy after percutaneous coronary intervention
Choudhary, Rahul
Kumari, Vimla
AMERICAN HEART JOURNAL, 2020, 230
[7] Impact of the Dual Antiplatelet Therapy Score on Clinical Outcomes in Acute Coronary Syndrome Patients Receiving P2Y12 Inhibitor Monotherapy
Huang, Sheng-Wei
Chen, Po-Wei
Feng, Wen-Han
Hsieh, I-Chang
Ho, Ming-Yun
Cheng, Chung-Wei
Yeh, Hung-, I
Chen, Ching-Pei
Huang, Wei-Chun
Fang, Ching-Chang
Lin, Hui-Wen
Lin, Sheng-Hsiang
Tsai, Chin-Feng
Su, Chun-Hung
Li, Yi-Heng
FRONTIERS IN CARDIOVASCULAR MEDICINE, 2022, 8
[8] Monotherapy with a P2Y12 inhibitor or aspirin for patients with established atherosclerosis: an updated meta-analysis
Cannata, Francesco
Chiarito, Mauro
Sanz-Sanchez, Jorge
Cao, Davide
Sturla, Matteo
Regazzoli, Damiano
Reimers, Bernhard
Condorelli, Gianluigi
Ferrante, Giuseppe
Stefanini, Giulio
EUROPEAN HEART JOURNAL SUPPLEMENTS, 2021, 23 (SUPPL G)
[9] Monotherapy with a P2Y12 inhibitor or aspirin for patients with established atherosclerosis: an updated meta-analysis
Cannata, Francesco
Chiarito, Mauro
Sanz-Sanchez, Jorge
Cao, Davide
Sturla, Matteo
Regazzoli, Damiano
Reimers, Bernhard
Condorelli, Gianluigi
Ferrante, Giuseppe
Stefanini, Giulio
EUROPEAN HEART JOURNAL SUPPLEMENTS, 2021, 23 (0G)
[10] P2Y12 Inhibitor With Or Without Aspirin In Patients With Hypertension Undergoing Percutaneous Coronary Intervention
Song, Pil-Sang
Choi, Si Wan
Jeong, Jin-Ok
HYPERTENSION, 2022, 79

← 1 2 3 4 5 →